# Monte Rosa Therapeutics, Inc.: financial statements, quarterly

GLUE · Nasdaq · CIK 1826457 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/glue.md) · [Financials](/companies/glue/financials.md) · [Filings](/companies/glue/filings.md) · [Insiders](/companies/glue/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/glue/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-122780.md) | [0.0 d](/filings/0000950170-25-042344.md) | [1.1](/filings/0000950170-25-066372.md) | [4.7](/filings/0000950170-25-104550.md) | [9.2](/filings/0001193125-25-268045.md) | [60.6 d](/filings/0001193125-26-109360.md) | [84.9](/filings/0001193125-26-210358.md) | [23.2](/filings/0001193125-26-336711.md) | [12.8](/filings/0001193125-25-268045.md) | [2.8 d](/filings/0001193125-26-109360.md) | [4.2](/filings/0001193125-26-210358.md) | [9.0](/filings/0001193125-26-336711.md) |
| Research and development | $m | [28.3](/filings/0000950170-24-122780.md) | [27.1 d](/filings/0000950170-25-042344.md) | [27.0](/filings/0000950170-25-066372.md) | [28.1](/filings/0000950170-25-104550.md) | [27.6](/filings/0001193125-25-268045.md) | [38.9 d](/filings/0001193125-26-109360.md) | [32.2](/filings/0001193125-26-210358.md) | [30.7](/filings/0001193125-26-336711.md) | [36.7](/filings/0001193125-25-268045.md) | [42.0 d](/filings/0001193125-26-109360.md) | [44.1](/filings/0001193125-26-210358.md) | [48.0](/filings/0001193125-26-336711.md) |
| Operating income | $m | [(37.0)](/filings/0000950170-24-122780.md) | [(34.9) d](/filings/0000950170-25-042344.md) | [(34.9)](/filings/0000950170-25-066372.md) | [(32.6)](/filings/0000950170-25-104550.md) | [(26.5)](/filings/0001193125-25-268045.md) | [13.0 d](/filings/0001193125-26-109360.md) | [44.0](/filings/0001193125-26-210358.md) | [(15.6)](/filings/0001193125-26-336711.md) | [(33.0)](/filings/0001193125-25-268045.md) | [(49.7) d](/filings/0001193125-26-109360.md) | [(50.0)](/filings/0001193125-26-210358.md) | [(49.1)](/filings/0001193125-26-336711.md) |
| Income tax | $m | [0.2](/filings/0000950170-24-122780.md) | [(0.0) d](/filings/0000950170-25-042344.md) | [0.1](/filings/0000950170-25-066372.md) | [0.3](/filings/0000950170-25-104550.md) | [0.1](/filings/0001193125-25-268045.md) | [2.2 d](/filings/0001193125-26-109360.md) | [0.8](/filings/0001193125-26-210358.md) | [1.2](/filings/0001193125-26-336711.md) | [(3.2)](/filings/0001193125-25-268045.md) | [0.1 d](/filings/0001193125-26-109360.md) | [0.1](/filings/0001193125-26-210358.md) | [0.2](/filings/0001193125-26-336711.md) |
| Net income | $m | [(34.9)](/filings/0000950170-24-122780.md) | [(33.3) d](/filings/0000950170-25-042344.md) | [(32.0)](/filings/0001193125-25-268045.md) | [(30.3)](/filings/0001193125-25-268045.md) | [(23.9)](/filings/0001193125-25-268045.md) | [13.4 d](/filings/0001193125-26-109360.md) | [46.9](/filings/0001193125-26-336711.md) | [(12.3)](/filings/0001193125-26-336711.md) | [(27.1)](/filings/0001193125-25-268045.md) | [(46.1) d](/filings/0001193125-26-336711.md) | [(44.5)](/filings/0001193125-26-336711.md) | [(43.4)](/filings/0001193125-26-336711.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [59.1](/filings/0000950170-24-122780.md) | [128](/filings/0000950170-25-042344.md) | [99.8](/filings/0000950170-25-066372.md) | [109](/filings/0000950170-25-104550.md) | [126](/filings/0001193125-25-268045.md) | [224](/filings/0001193125-26-109360.md) | [78.5](/filings/0001193125-26-210358.md) | [69.4](/filings/0001193125-26-336711.md) | [208](/filings/0001193125-25-268045.md) | [130](/filings/0001193125-26-336711.md) | [160](/filings/0001193125-26-210358.md) | [90.1](/filings/0001193125-26-336711.md) |
| Current assets | $m | [183](/filings/0000950170-23-061995.md) | [236](/filings/0000950170-25-042344.md) | [199](/filings/0000950170-24-056288.md) | [278](/filings/0000950170-24-093296.md) | [251](/filings/0000950170-24-122780.md) | [377](/filings/0001193125-26-109360.md) | [332](/filings/0000950170-25-066372.md) | [299](/filings/0000950170-25-104550.md) | [402](/filings/0001193125-25-268045.md) | [393](/filings/0001193125-26-336711.md) | [678](/filings/0001193125-26-210358.md) | [631](/filings/0001193125-26-336711.md) |
| Total assets | $m | [252](/filings/0000950170-23-061995.md) | [304](/filings/0000950170-25-042344.md) | [267](/filings/0000950170-24-056288.md) | [344](/filings/0000950170-24-093296.md) | [315](/filings/0000950170-24-122780.md) | [439](/filings/0001193125-26-109360.md) | [393](/filings/0000950170-25-066372.md) | [360](/filings/0000950170-25-104550.md) | [460](/filings/0001193125-25-268045.md) | [449](/filings/0001193125-26-336711.md) | [736](/filings/0001193125-26-210358.md) | [691](/filings/0001193125-26-336711.md) |
| Current liabilities | $m | [22.6](/filings/0000950170-23-061995.md) | [46.6](/filings/0000950170-25-042344.md) | [41.3](/filings/0000950170-24-056288.md) | [42.3](/filings/0000950170-24-093296.md) | [41.6](/filings/0000950170-24-122780.md) | [157](/filings/0001193125-26-109360.md) | [59.2](/filings/0000950170-25-066372.md) | [41.9](/filings/0000950170-25-104550.md) | [61.4](/filings/0001193125-25-268045.md) | [64.2](/filings/0001193125-26-336711.md) | [71.0](/filings/0001193125-26-210358.md) | [59.7](/filings/0001193125-26-336711.md) |
| Total liabilities | $m | [67.6](/filings/0000950170-23-061995.md) | [125](/filings/0000950170-25-042344.md) | [114](/filings/0000950170-24-056288.md) | [119](/filings/0000950170-24-093296.md) | [110](/filings/0000950170-24-122780.md) | [216](/filings/0001193125-26-109360.md) | [118](/filings/0000950170-25-066372.md) | [91.5](/filings/0000950170-25-104550.md) | [214](/filings/0001193125-25-268045.md) | [216](/filings/0001193125-26-336711.md) | [215](/filings/0001193125-26-210358.md) | [204](/filings/0001193125-26-336711.md) |
| Shareholders' equity | $m | [185](/filings/0000950170-24-122780.md) | [179](/filings/0001193125-26-109360.md) | [153](/filings/0001193125-25-268045.md) | [225](/filings/0001193125-25-268045.md) | [205](/filings/0001193125-25-268045.md) | [223](/filings/0001193125-26-336711.md) | [275](/filings/0001193125-26-336711.md) | [268](/filings/0001193125-26-336711.md) | [246](/filings/0001193125-25-268045.md) | [233](/filings/0001193125-26-336711.md) | [522](/filings/0001193125-26-336711.md) | [487](/filings/0001193125-26-336711.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(24.7) d](/filings/0000950170-24-122780.md) | [29.6 d](/filings/0000950170-25-042344.md) | [(38.2)](/filings/0000950170-25-066372.md) | [(27.8) d](/filings/0000950170-25-104550.md) | [(21.0) d](/filings/0001193125-25-268045.md) | [129 d](/filings/0001193125-26-109360.md) | [(45.5)](/filings/0001193125-26-210358.md) | [(34.7) d](/filings/0001193125-26-336711.md) | [100 d](/filings/0001193125-25-268045.md) | [(43.0) d](/filings/0001193125-26-109360.md) | [(37.4)](/filings/0001193125-26-210358.md) | [(44.1) d](/filings/0001193125-26-336711.md) |
| Capital expenditure | $m | [1.7 d](/filings/0000950170-24-122780.md) | [1.7 d](/filings/0000950170-25-042344.md) | [1.4](/filings/0000950170-25-066372.md) | [2.0 d](/filings/0000950170-25-104550.md) | [0.4 d](/filings/0001193125-25-268045.md) | [0.2 d](/filings/0001193125-26-109360.md) | [1.6](/filings/0001193125-26-210358.md) | [1.7 d](/filings/0001193125-26-336711.md) | [0.7 d](/filings/0001193125-25-268045.md) | [0.8 d](/filings/0001193125-26-109360.md) | [1.9](/filings/0001193125-26-210358.md) | [4.7 d](/filings/0001193125-26-336711.md) |
| Dividends paid | $m | [0.0 d](/filings/0000950170-23-061995.md) | [0.0 d](/filings/0000950170-24-031150.md) | [0.0](/filings/0000950170-24-056288.md) | [0.0 d](/filings/0000950170-24-093296.md) | [0.0 d](/filings/0000950170-24-122780.md) | [0.0 d](/filings/0000950170-25-042344.md) | [0.0](/filings/0000950170-25-066372.md) | [0.0 d](/filings/0000950170-25-104550.md) | [0.0 d](/filings/0001193125-25-268045.md) | [0.0 d](/filings/0001193125-26-109360.md) | [0.0](/filings/0001193125-26-210358.md) | [0.0 d](/filings/0001193125-26-336711.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [46.7](/filings/0000950170-23-061995.md) | [49.3](/filings/0000950170-24-056288.md) | [49.4](/filings/0000950170-24-093296.md) | [49.8](/filings/0000950170-24-122780.md) | [60.2](/filings/0000950170-25-066372.md) | [71.2](/filings/0000950170-25-104550.md) | [82.0](/filings/0001193125-25-268045.md) | [83.0](/filings/0001193125-26-210358.md) | [82.2](/filings/0001193125-26-336711.md) | [82.4](/filings/0001193125-25-268045.md) | [99.9](/filings/0001193125-26-210358.md) | [101](/filings/0001193125-26-336711.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 85,313,401 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336711.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.